CUAMC
FDMT icon

China Universal Asset Management Company’s 4D Molecular Therapeutics FDMT Stock Holding History

China Universal Asset Management Company’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$111K Sell
8,320
-732
-8% -$7.13K 0.01% 409
2026
Q1 		$84.3K Sell
9,052
-258
-3% -$2.25K 0.01% 423
2025
Q4 		$69.8K Buy
9,310
+1,124
+14% +$11.4K 0.01% 434
2025
Q3 		$71.1K Sell
8,186
-1,118
-12% -$6.68K 0.01% 410
2025
Q2 		$34.5K Buy
9,304
+17
+0.2% +$60 ﹤0.01% 439
2025
Q1 		$30K Sell
9,287
-515
-5% -$2.43K ﹤0.01% 446
2024
Q4 		$54.6K Sell
9,802
-193
-2% -$1.51K 0.01% 447
2024
Q3 		$108K Buy
9,995
+3,922
+65% +$65.1K 0.01% 352
2024
Q2 		$127K Sell
6,073
-3,506
-37% -$88K 0.02% 283
2024
Q1 		$305K Buy
9,579
+4,628
+93% +$118K 0.04% 242
2023
Q4 		$100K Buy
4,951
+3,873
+359% +$51K 0.02% 277
2023
Q3 		$13.7K Buy
1,078
+529
+96% +$8.85K ﹤0.01% 325
2023
Q2 		$9.92K Buy
549
+110
+25% +$2.02K ﹤0.01% 319
2023
Q1 		$7.55K Buy
439
+110
+33% +$2.14K ﹤0.01% 329
2022
Q4 		$7.31K Buy
329
+26
+9% +$402 ﹤0.01% 255
2022
Q3 		$2K Buy
+303
New +$2.74K ﹤0.01% 348

Other funds holding FDMT

JT
Jupiter Topco New York $245B AUM
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM

China Universal Asset Management Company's FDMT Position: Q2 2026 in Review

China Universal Asset Management Company reduced its 4D Molecular Therapeutics (FDMT) stake by 8.1% in Q2 2026, selling an estimated $7.13K and leaving 8,320 shares worth $111K. The position accounts for 0.01% of the portfolio, ranked #409.

China Universal Asset Management Company first reported a position in FDMT in Q3 2022 and has held it in 16 quarters since. The position peaked at $305K in Q1 2024. 157 funds tracked by Wall St. Rank hold FDMT as of Q2 2026.

  • China Universal Asset Management Company held 8,320 shares of 4D Molecular Therapeutics worth $111K as of Q2 2026.
  • China Universal Asset Management Company sold 732 4D Molecular Therapeutics shares in Q2 2026, an estimated $7.13K.
  • 4D Molecular Therapeutics made up 0.01% of China Universal Asset Management Company's portfolio in Q2 2026, its #409 holding.
  • China Universal Asset Management Company first reported a position in 4D Molecular Therapeutics in Q3 2022 and has held it in 16 quarters since.
  • China Universal Asset Management Company's 4D Molecular Therapeutics position peaked at $305K in Q1 2024.
  • 157 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2026.

Based on China Universal Asset Management Company's 13F filing for Q2 2026, filed 24 Jul 2026.